You are here


Member Since 2004

David Fredrickson

Executive Vice-President, Global Head Oncology Business Unit

Dave Fredrickson was appointed EVP, Global Head Oncology Business Unit in October 2017 and is responsible for driving growth and maximizing commercial performance of the global oncology and haematology portfolio within AstraZeneca. In addition, he plays a critical leadership role in setting the Oncology portfolio and product strategy for the organisation.

Prior to this role, Dave served as President of AstraZeneca K.K. in Japan, and Vice President, Specialty Care for AstraZeneca in the United States, spanning oncology, infection disease, and neuroscience medicines. Dave joined AstraZeneca from Roche/Genentech in 2014, where he was Business Unit Manager, Oncology in Spain and held growing commercial responsibilities in strategy, marketing and sales in the US.  He also served for nine years at the Monitor Group, LLC (now Monitor Deloitte Group, LLC), a global strategy consultancy. He has served as Vice Chairman of European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan and was a member of the Board of the Japan Pharmaceutical Manufacturers Association (JPMA).  He is a graduate of Georgetown University (DC) in Government.

CEO Roundtable on Cancer

Charles A. Sanders Life Sciences  Award Winner

2014 Recipient

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2006

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Andrew Coop. Vice President, US Medical Affairs; David Fredrickson, Executive Vice President & Global Head of Oncology; Michelle Werner MBA, Country President for Nordics & Baltic Markets in Europe; Nevine Zariffa, Vice President

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Pioneering Data Provider

Further Support

Founding Member, CEO Roundtable on Cancer - China


AstraZeneca is a global, science-led biopharmaceutical company that spans the discovery, development, manufacturing, distribution and worldwide commercialisation of primary care and speciality care medicines.

We believe the best way we can help patients is to focus on breakthrough science in order to uncover disease mechanisms and develop novel, targeted therapies that interact with them. This is at the heart of our purpose as a company: to push the boundaries of science to deliver life-changing medicines.

We invest in distinctive science in three main therapy areas where we believe we can make the most meaningful difference to patients: oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity. Our science exploits our rare combination of capabilities in small molecules and biologics, immunotherapies, protein engineering technologies and devices. These are reinforced by a strong focus on translational science and personalised healthcare capabilities. We build on our own capabilities by collaborating with world-renowned scientists and academic institutions and partnering with like-minded science-led companies.

Through leading in science, we are confident that we can transform the lives of people around the world and deliver value to our shareholders.

For more information, visit
Pharmaceutical, Biopharmaceutical, Innovation, Research and development, Global business